NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/09/2024
Back to search
Official data from USPTO
EASTON BIOPHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
21
Latest update
07/09/2024
Trademark type
Combined
Nice classes
5
Filing date
08/30/2022
Registration date
07/09/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/09/2024
Last transaction
07/09/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
3
Owner type
99
Owner location
CHENGDU HIGH TECH ZONE, CN
Examiner
BERLIN, JUSTIN E
Law office
N70
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of a circular figure comprised of two arrows, two chevrons, and a line, followed by four Chinese characters, and the wording EASTON BIOPHARMACEUTICALS.
Holders and representatives
Holders
Chengdu Easton Biopharmaceuticals Co., Ltd.
Representatives
John Alumit ALUMIT IP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Antidotes; Analgesic preparations; Anti-sarcoma preparations; Cardiovascular treatment preparations; Cardiovascular pharmaceuticals; Chemical preparations for pharmaceutical or medical purposesfor the prevention of neurological diseases; General anesthetics; Medicinal infusions for treating diabetes; Nasal spray preparations; Nasal sprays for medical purposes; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for the treatment and prevention of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary systemfor the treatment of inflammatory disordersfor use in dermatologyoncologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders; Pharmaceutical products for the prevention and treatment of cancer; Prescription and non-prescription medicinespillstabletscapsulescapletsliquid dropssachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Medicines for the treatment of cardiovascular and cerebrovascular diseases; Pharmaceutical preparations for suppressing tumors; Pharmaceuticalspsychotropics
Publications
History of USPTO decisions and trademark events.
21 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/09/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/23/2024
PUBO
PUBLISHED FOR OPPOSITION
04/23/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/03/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/14/2024
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
03/14/2024
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
08/08/2023
ISPO
WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST
08/08/2023
44EM
44(e) PETITION - DISMISSED
08/08/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/08/2023
PUBO
PUBLISHED FOR OPPOSITION
08/08/2023
APET
ASSIGNED TO PETITION STAFF
08/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/19/2023
44EP
44(e) PETITION - RECEIVED
07/18/2023
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
07/18/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/06/2023
DOCK
ASSIGNED TO EXAMINER
06/15/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
09/20/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/18/2022
NWAP
NEW APPLICATION ENTERED
09/02/2022
Continuous trademark protection
Get notified about every new filing that threatens EASTON BIOPHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.